Quarter Period Statement Of Income

Takeda Pharmaceutical Company Limited - Filing #7251660

Concept 2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2024-04-01 to
2025-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
2023-04-01 to
2024-03-31
Quarter period statement of income
Statement of income
Net sales
580,360,000,000 JPY
595,575,000,000 JPY
Cost of sales
258,904,000,000 JPY
245,505,000,000 JPY
Gross profit (loss)
321,456,000,000 JPY
350,070,000,000 JPY
Selling, general and administrative expenses
284,559,000,000 JPY
302,001,000,000 JPY
Selling, general and administrative expenses
Sales commission
33,872,000,000 JPY
32,951,000,000 JPY
Salaries
28,701,000,000 JPY
29,009,000,000 JPY
Depreciation
7,921,000,000 JPY
7,792,000,000 JPY
Operating profit (loss)
36,897,000,000 JPY
48,070,000,000 JPY
Non-operating income
Non-operating income
211,842,000,000 JPY
391,614,000,000 JPY
Non-operating expenses
Non-operating expenses
162,145,000,000 JPY
153,285,000,000 JPY
Ordinary profit (loss)
86,594,000,000 JPY
286,399,000,000 JPY
Extraordinary income
Extraordinary income
134,776,000,000 JPY
138,488,000,000 JPY
Extraordinary losses
Extraordinary losses
22,038,000,000 JPY
33,545,000,000 JPY
Profit (loss) before income taxes
199,332,000,000 JPY
391,342,000,000 JPY
Income taxes - current
-705,000,000 JPY
20,281,000,000 JPY
Income taxes - deferred
47,217,000,000 JPY
32,187,000,000 JPY
Income taxes
46,512,000,000 JPY
52,468,000,000 JPY
Profit (loss)
JPY
JPY
152,820,000,000 JPY
152,820,000,000 JPY
152,820,000,000 JPY
152,820,000,000 JPY
JPY
338,874,000,000 JPY
JPY
338,874,000,000 JPY
338,874,000,000 JPY
338,874,000,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.